Connect Biopharma is trading at $2.45 (+11.09%), with investors possibly positioning ahead of August 12, 2026 earnings.
- No new company-specific announcement dated August 10, 2026, was identified in available reliable coverage.
- Anticipated early-September rademikibart asthma data and the earnings report are not confirmed as direct catalysts.
- Broader markets are modestly firmer, though the Nasdaq’s +0.43% move alone does not clearly explain the gain.